102 related articles for article (PubMed ID: 23358329)
1. Effects of moxifloxacin on serum glucose concentrations in rats.
Ishiwata Y; Takahashi Y; Nagata M; Yasuhara M
Biol Pharm Bull; 2013; 36(4):686-90. PubMed ID: 23358329
[TBL] [Abstract][Full Text] [Related]
2. Gatifloxacin-induced histamine release and hyperglycemia in rats.
Ishiwata Y; Yasuhara M
Eur J Pharmacol; 2010 Oct; 645(1-3):192-7. PubMed ID: 20674567
[TBL] [Abstract][Full Text] [Related]
3. Effect of levofloxacin on serum glucose concentration in rats.
Ishiwata Y; Itoga Y; Yasuhara M
Eur J Pharmacol; 2006 Dec; 551(1-3):168-74. PubMed ID: 17026994
[TBL] [Abstract][Full Text] [Related]
4. Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies.
Gavin JR; Kubin R; Choudhri S; Kubitza D; Himmel H; Gross R; Meyer JM
Drug Saf; 2004; 27(9):671-86. PubMed ID: 15230648
[TBL] [Abstract][Full Text] [Related]
5. The effect of levofloxacin and moxifloxacin on cardiovascular functions of rats with streptozotocin-induced diabetes.
Absi M; Ghareeb H; Khalil A; Ruegg UT
Diab Vasc Dis Res; 2013 Jan; 10(1):65-71. PubMed ID: 22621918
[TBL] [Abstract][Full Text] [Related]
6. Effect of fluoroquinolones on mitochondrial function in pancreatic beta cells.
Ghaly H; Jörns A; Rustenbeck I
Eur J Pharm Sci; 2014 Feb; 52():206-14. PubMed ID: 24284031
[TBL] [Abstract][Full Text] [Related]
7. Effects of gatifloxacin on serum glucose concentration in normal and diabetic rats.
Ishiwata Y; Sanada Y; Yasuhara M
Biol Pharm Bull; 2006 Mar; 29(3):527-31. PubMed ID: 16508159
[TBL] [Abstract][Full Text] [Related]
8. Mechanism Underlying Induction of Hyperglycemia in Rats by Single Administration of Olanzapine.
Nagata M; Nakajima M; Ishiwata Y; Takahashi Y; Takahashi H; Negishi K; Yasuhara M
Biol Pharm Bull; 2016; 39(5):754-61. PubMed ID: 27150145
[TBL] [Abstract][Full Text] [Related]
9. Effect of moxifloxacin on bacterial pathogenicity factors in comparison with amoxicillin, clarithromycin and ceftriaxone.
Drago L; De Vecchi E; Nicola L; Tocalli L; Gismondo MR
J Chemother; 2004 Feb; 16(1):30-7. PubMed ID: 15077996
[TBL] [Abstract][Full Text] [Related]
10. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
Malhotra-Kumar S; Van Heirstraeten L; Lammens C; Chapelle S; Goossens H
J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051
[TBL] [Abstract][Full Text] [Related]
11. Antibacterial effects of moxifloxacin and levofloxacin simulating epithelial lining fluid concentrations against community-acquired methicillin-resistant Staphylococcus aureus.
Lee SY; Fan HW; Sutherland C; DeRyke AC; Nicolau DP
Drugs R D; 2007; 8(2):69-77. PubMed ID: 17324004
[TBL] [Abstract][Full Text] [Related]
12. Comparative in vitro and in vivo antimicrobial activities of sitafloxacin, gatifloxacin and moxifloxacin against Mycobacterium avium.
Sano C; Tatano Y; Shimizu T; Yamabe S; Sato K; Tomioka H
Int J Antimicrob Agents; 2011 Apr; 37(4):296-301. PubMed ID: 21353489
[TBL] [Abstract][Full Text] [Related]
13. In vitro antimicrobial activity of moxifloxacin against bacterial strains isolated from blood of neutropenic cancer patients.
Cometta A; Marchetti O; Calandra T; Bille J; Kern WV; Zinner S;
Eur J Clin Microbiol Infect Dis; 2006 Aug; 25(8):537-40. PubMed ID: 16896825
[No Abstract] [Full Text] [Related]
14. Comparative pharmacodynamics of garenoxacin, gemifloxacin, and moxifloxacin in community-acquired pneumonia caused by Streptococcus pneumoniae: a Monte Carlo simulation analysis.
Noreddin AM; Reese AA; Ostroski M; Hoban DJ; Zhanel GG
Clin Ther; 2007 Dec; 29(12):2685-9. PubMed ID: 18201584
[TBL] [Abstract][Full Text] [Related]
15. Moxifloxacin and biofilm production by coagulase-negative staphylococci.
Pérez-Giraldo C; Gonzalez-Velasco C; Sánchez-Silos RM; Hurtado C; Blanco MT; Gómez-García AC
Chemotherapy; 2004 Jun; 50(2):101-4. PubMed ID: 15211086
[TBL] [Abstract][Full Text] [Related]
16. [The basic and clinical studies of moxifloxacin: the profile as respiratory quinolones].
Kohno S
Jpn J Antibiot; 2005 Oct; 58(5):431-44. PubMed ID: 16379155
[No Abstract] [Full Text] [Related]
17. Streptococcus pneumoniae: susceptibility to penicillin and moxifloxacin.
Rossi F; Franco MR; Rodrigues HM; Andreazzi D
J Bras Pneumol; 2012; 38(1):66-71. PubMed ID: 22407042
[TBL] [Abstract][Full Text] [Related]
18. A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia.
Morganroth J; Dimarco JP; Anzueto A; Niederman MS; Choudhri S;
Chest; 2005 Nov; 128(5):3398-406. PubMed ID: 16304291
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the mutant selection window for fluoroquinolones against Neisseria gonorrhoeae.
Allen GP; Hankins CD
J Antimicrob Chemother; 2009 Aug; 64(2):359-63. PubMed ID: 19460783
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of hERG K+ channel blockade by the fluoroquinolone antibiotic moxifloxacin.
Alexandrou AJ; Duncan RS; Sullivan A; Hancox JC; Leishman DJ; Witchel HJ; Leaney JL
Br J Pharmacol; 2006 Apr; 147(8):905-16. PubMed ID: 16474415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
